Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2006

Study Completion Date

September 30, 2008

Conditions
Melanoma
Interventions
DRUG

ATN-224

DRUG

Temozolomide

Trial Locations (17)

20817

Center for Cancer and Blood Disorders, Bethesda

21237

The Harry and Jeanette Weinberg Cancer Institute at Franklin Square, Baltimore

29605

Cancer Center of the Carolinas, Greenville

33901

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, Nashville

45242

Oncology Hematology Care, Cincinati

59101

Billings Clinic, Billings

70006

Hematology and Oncology Specialists, LLC, Metairie

75246

Mary Crowley Medical Research Center, Dallas

80262

University of Colorado Health Science Center, Denver

85724

Arizona Cancer Center, Tucson

90404

The Angeles Clinic, Santa Monica

92024

Pacific Oncology and Hematology, Encinitas

92868

Hematology - Oncology Group of Orange, Inc., Orange

UCI Chao Family Comprehensive Cancer Center, Orange

07042

Mountainside Hospital Cancer Center - The Melanoma Center, Montclair

Unknown

Chattanooga Oncology and Hematology Associates, Chattanooga

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Attenuon

INDUSTRY